Healthcare / BiotechnologyBSE
$456.60
-10.70 (-2.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $106.8M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.9B
P/E
69.5x
↑EV/EBITDA
43.0x
↑ROE
16.5%
↑Gross Margin
53.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+12.7%
FCF CAGR
+39.9%
FCF margin
10.2%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.06B · net income $298.9M · FCF $211.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.06B | $2.06B | $1.56B | $1.64B | $1.44B |
| Net Income | $298.9M | $298.9M | $215.3M | $248.5M | $248.4M |
| EBITDA | $440.1M | $440.1M | $293.4M | $358.0M | $312.8M |
| EPS | — | — | 5.21 | 6.01 | 6.01 |
| Gross Margin | 53.3% | 53.3% | 53.6% | 53.9% | 40.5% |
| Operating Margin | 16.3% | 16.3% | 13.6% | 18.9% | 18.7% |
| Net Margin | 14.5% | 14.5% | 13.8% | 15.1% | 17.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.06 | 0.08 |
| Current Ratio | 3.28 | 3.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $211.1M | $211.1M | $106.8M | $14.6M | $77.1M |
| Returns | |||||
| ROE | 16.5% | 16.5% | 14.0% | 18.6% | 22.6% |
| Valuation | |||||
| P/E | 69.50 | 69.50 | 18.22 | 18.61 | 7.09 |
| EV/EBITDA | 42.96 | 42.96 | 13.29 | 13.07 | 5.75 |
| P/B | 10.39 | 10.39 | 2.56 | 3.46 | 1.60 |
| Growth & Yield | |||||
| Revenue Growth | 31.8% | 31.8% | -4.6% | 13.9% | — |
| EPS Growth | — | — | -13.4% | 0.0% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+385.0%
Start / end P/E
n/dx → n/dx
EPS bridge
5.21 → n/d
Residual
+384.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.